



**Veterinary
Medicines
Directorate**

**United Kingdom
Veterinary Medicines Directorate
Woodham Lane
New Haw
Addlestone
Surrey KT15 3LS**

NATIONAL PROCEDURE

**PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY
MEDICINAL PRODUCT**

AceSedate 2 mg/ml Solution for Injection for Dogs and Cats

Date Created: July 2018

MODULE 1

PRODUCT SUMMARY

Name, strength and pharmaceutical form	AceSedate 2 mg/ml Solution for Injection for Dogs and Cats
Applicant	Jurox (UK) Limited Richmond House, Second Floor 105 High Street Crawley West Sussex RH10 1DD United Kingdom
Active substance	Acepromazine Maleate
ATC Vetcode	QN05AA04
Target species	Dogs and Cats
Indication for use	<p><i>Anaesthetic Premedication:</i> Following acepromazine administration, the amount of anaesthetic necessary to induce anaesthesia is considerably reduced. This reduction is approximately one-third of a suitable induction agent.</p> <p><i>Tranquilisation:</i> Acepromazine tranquilisation (ataraxy) involves a modification of temperament which is not associated with hypnosis, narcosis or marked sedation. This is achieved with low doses of acepromazine.</p> <p><i>Sedation:</i> At higher dose rates acepromazine is a sedative.</p>

MODULE 2

The Summary of Product Characteristics (SPC) for this product is available on the Product Information Database of the Veterinary Medicines Directorate.

www.gov.uk/check-animal-medicine-licensed

MODULE 3

PUBLIC ASSESSMENT REPORT

Legal basis of original application	A generic application in accordance with Article 13(1) of Directive 2001/82/EC as amended.
Date of conclusion of the procedure	11/06/2018

I. SCIENTIFIC OVERVIEW

AceSedate 2 mg/ml Solution for Injection for Dogs and Cats has been developed as a generic of ACP Injection 2mg/ml Solution for injection which has been authorised since 1992.

The product is indicated for anaesthetic premedication; following acepromazine administration, the amount of anaesthetic necessary to induce anaesthesia is considerably reduced. This reduction is approximately one-third of a suitable induction agent. Tranquilisation; acepromazine tranquilisation (ataraxy) involves a modification of temperament which is not associated with hypnosis, narcosis or marked sedation; this is achieved with low doses of acepromazine. At higher dose rates acepromazine is a sedative.

The product is contraindicated in pregnant animals and should not be used on a long-term basis in individual animals.

The product is produced and controlled using validated methods and tests which ensure the consistency of the product released on the market. It has been shown that the product can be safely used in the target species, any reactions observed are indicated in the SPC.¹ The product is safe for the user, and for the environment, when used as recommended. Suitable warnings and precautions are indicated in the SPC. The efficacy² of the product was demonstrated according to the claims made in the SPC. The overall benefit/risk analysis is in favour of granting a marketing authorisation.

¹ SPC – Summary of product Characteristics.

² Efficacy – The production of a desired or intended result.

II. QUALITATIVE AND QUANTITATIVE PARTICULARS OF THE CONSTITUENTS

II.A. Composition

The product contains Acepromazine 2.0 mg (as acepromazine maleate 2.71 mg) and the excipients phenol, sodium hydrochloride (for pH adjustment), maleic acid (for pH adjustment) and water for injections.

The container/closure system consists of an amber Type I glass vial of 20ml, closed with a chlorobutyl rubber stopper and sealed with an aluminium crimped seal with plastic flip-off cap. The particulars of the containers and controls performed are provided and conform to the regulation.

The choice of the formulation and the presence of preservative are justified. The product is an established pharmaceutical form and its development is adequately described in accordance with the relevant European guidelines.

II.B. Description of the Manufacturing Method

The product is manufactured fully in accordance with the principles of good manufacturing practice from a licensed manufacturing site. The manufacturing method consists of solubilisation of the ingredients, pH adjustment, filling into vials and terminal sterilisation. Process validation data on the product have been presented in accordance with the relevant European guidelines.

II.C. Control of Starting Materials

The active substance is acepromazine maleate, an established active substance described in the British Veterinary Pharmacopoeia and United States Pharmacopoeia. The active substance is manufactured in accordance with the principles of good manufacturing practice.

The active substance specification is considered adequate to control the quality of the material. Batch analytical data demonstrating compliance with this specification have been provided.

Acepromazine maleate is sourced from a single supplier in accordance with an active substance master file.

Phenol, sodium hydroxide, maleic acid and water for injections are tested against their respective monographs in the current European Pharmacopoeia (Ph.Eur). Certificates of analysis have been provided.

Acepromazine maleate is supplied in light-resistant fibreboard drums doubly lined with new clean, antistatic, low-density polyethylene bags meeting Ph.Eur. 3.13 *Polyolefins* standards. The bags are sealed with plastic bag ties.

II.C.4. Substances of Biological Origin

There are no substances within the scope of the TSE Guideline present or used in the manufacture of this product.

II.D. Control Tests Carried Out at Intermediate Stages of the Manufacturing Process

Not applicable.

II.E. Control Tests on the Finished Product

The finished product specification controls the relevant parameters for the pharmaceutical form. The tests in the specification, and their limits, have been justified and are considered appropriate to adequately control the quality of the product. Control tests on the finished product include those for identification, assay and pH.

II.F. Stability

Stability data on the active substance have been provided in accordance with applicable European guidelines, demonstrating the stability of the active substance when stored under the approved conditions. A retest period of 4 years is supported by the stability data in the active substance master file.

Stability data on the finished product have been provided in accordance with applicable European guidelines, demonstrating the stability of the product throughout its shelf life when stored under the approved conditions.

G. Other Information

Shelf life of the veterinary medicinal product as packaged for sale: 2 years.

Shelf life after opening of the immediate packaging: 28 days.

Do not store above 30°C.

Keep the vial in the outer carton in order to protect from light.

Do not freeze.

III. SAFETY AND RESIDUES DOCUMENTATION (PHARMACOTOXICOLOGICAL)

As this is a generic application according to Article 13(1) of Directive 2001/82/EC, as amended, and bioequivalence with the reference product has been demonstrated, results of pharmacological and toxicological tests are not required.

Warnings and precautions as listed on the product literature are the same as those of the reference product and are adequate to ensure safety of the product to users and the environment.

III.A Safety Documentation

User Safety

A user risk assessment was provided in compliance with the relevant guideline which considers the risk following accidental self-injection and skin and eye irritation. These risks have been mitigated by adequate warnings on the product literature. The risks to the user are considered to be the same as those for the reference product. Warnings and precautions as listed on the product literature are adequate to ensure safety to users of the product. Therefore the following applicant's user recommendations are appropriate:

- This product contains a potent sedative; care should be taken when handling and administering this product to avoid accidental self-exposure. In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician but **DO NOT DRIVE** as sedation may occur. Symptomatic treatment may be required.
- This product may cause irritation of skin and eyes. Avoid contact with skin and eyes. If accidental eye contact occurs, flush gently with fresh running water for 15 minutes and seek medical advice if any irritation persists. In the event of accidental skin contact, wash the contaminated area with large amounts of soap and water. Medical advice should be sought if irritation persists.
- Wash hands and exposed skin thoroughly after use.

Environmental Safety

The Environmental Risk Assessment (ERA) was carried out in accordance with VICH and CVMP guidelines.

Phase I:

The product will only be used in non-food animals and as a result environmental exposure will be low. A Phase II ERA was not required.

IV. CLINICAL DOCUMENTATION

IV.I. Pre-Clinical Studies

Pharmacology

An *in vivo* bioequivalence study was not required for this product, as exemption from providing these data was accepted under the guideline EMA/CVMP/016/00-Rev.2, whereby the product and the reference product are demonstrated to be essentially similar.

Tolerance in the Target Species

Tolerance studies were not required because the product and the reference product are quantitatively and qualitatively the same in terms of the active substance, and can be considered bioequivalent.

Resistance

Resistance studies were not required because the product and the reference product are quantitatively and qualitatively the same in terms of the active substance, and can be considered bioequivalent.

IV.II. Clinical Documentation

As this is a generic application according to Article 13(1) of Directive 2001/82/EC as amended, and bioequivalence with the reference product has been demonstrated, clinical studies are not required.

V OVERALL CONCLUSION AND BENEFIT– RISK ASSESSMENT

The data submitted in the dossier demonstrate that when the product is used in accordance with the Summary of Product Characteristics the benefit/risk profile of the product is favourable.

MODULE 4

POST-AUTHORISATION ASSESSMENTS

The SPC and package leaflet may be updated to include new information on the quality, safety and efficacy of the veterinary medicinal product. The current SPC is available on the Product Information Database of the Veterinary Medicines Directorate website.

(www.gov.uk/check-animal-medicine-licensed)

The post-authorisation assessment (PAA) contains information on significant changes which have been made after the original procedure which are important for the quality, safety or efficacy of the product.

The PAA for this product is available on the Product Information Database of the Veterinary Medicines Directorate website.

(www.gov.uk/check-animal-medicine-licensed)